Bharat Biotech has recruited 23,000 volunteers so far for the Phase III clinical trials of its COVID-19 vaccine candidate, ‘Covaxin’.
“Bharat Biotech has announced successful recruitment of 23,000 volunteers, and continued progress towards achieving the goal of 26,000 participants for Phase-3 clinical trial of coronavirus vaccine Covaxin across multiple sites in India,” an official statement read.
Covaxin, India’s indigenous COVID-19 vaccine by Bharat Biotech is developed in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV).
This indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3) bio-containment facility, one of its kind in the world.
The phase III human clinical trials of Covaxin began mid-November, targeted to be done in 26,000 volunteers across India, according to Bharat Biotech.
This is India’s first and only Phase III efficacy study for a COVID-19…
